Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...

(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...

Abstract: A novel weighed and summing bipolar photonic digital-to-analog converter (BPDAC) scheme employing optical differential phase shift keying modulation and balanced detection is proposed and ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Sjögren’s disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine ...